MGNX - MacroGenics Inc Stock Price, Fair Value and News

4.36USD-0.76 (-14.84%)Market Closed

Market Summary

USD4.36-0.76

Market Closed

-14.84%

MGNX Alerts

Big fall in Revenue (Y/Y)

Big fall in earnings (Y/Y)
Losses in recent quarter

MGNX Stock Price

View Fullscreen

MGNX RSI Chart

MGNX Valuation

Market Cap

273.1M

Price/Earnings (Trailing)

-11.75

Price/Sales (Trailing)

6.3

Price/Free Cashflow

-2.4

MGNX Price/Sales (Trailing)

MGNX Profitability

Return on Equity

-21.89%

Return on Assets

-9.36%

Free Cashflow Yield

-41.7%

MGNX Fundamentals

MGNX Revenue

Revenue (TTM)

43.4M

Rev. Growth (Yr)

-62.83%

Rev. Growth (Qtr)

-15.07%

MGNX Earnings

Earnings (TTM)

-23.2M

Earnings Growth (Yr)

-37.31%

Earnings Growth (Qtr)

-13.28%

Breaking Down MGNX Revenue

Last 7 days

31.7%

Last 30 days

-72.9%

Last 90 days

-74.8%

Trailing 12 Months

-25.0%

How does MGNX drawdown profile look like?

MGNX Financial Health

Current Ratio

3.63

MGNX Investor Care

Shares Dilution (1Y)

1.28%

Diluted EPS (TTM)

-0.39

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	43.4M	0	0	0
2023	165.3M	152.5M	121.1M	58.7M
2022	71.7M	66.9M	93.0M	151.9M
2021	108.1M	118.6M	116.0M	77.4M
2020	68.2M	77.9M	77.4M	104.9M
2019	65.1M	56.8M	54.8M	64.2M
2018	133.3M	108.9M	84.5M	60.1M
2017	108.3M	124.8M	141.3M	157.7M
2016	98.6M	96.4M	94.1M	91.9M
2015	104.4M	101.9M	98.2M	100.9M
2014	62.2M	59.1M	57.2M	47.8M
2013	53.9M	48.8M	52.9M	58.0M
2012	58.9M	60.5M	62.2M	63.8M
2011	0	0	0	57.2M

Get all data in R, Python etc through our Historical Stock Data APIs

GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224

Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index

Very Expensive Stocks

Very Cheap Stocks

Try For Just $1.99

Tracking the Latest Insider Buys and Sells of MacroGenics Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 04, 2024	peters jeffrey stuart	sold	-799,148	15.5491	-51,395	senior vp and general counsel
Apr 04, 2024	peters jeffrey stuart	acquired	204,850	4.82	42,500	senior vp and general counsel
Mar 06, 2024	peters jeffrey stuart	acquired	213,875	10.8981	19,625	senior vp and general counsel
Mar 06, 2024	peters jeffrey stuart	sold	-421,938	21.5	-19,625	senior vp and general counsel
Mar 04, 2024	spitznagel thomas	acquired	115,000	11.5	10,000	sr vp, technical ops
Mar 04, 2024	karrels james	sold	-615,000	20.5	-30,000	svp, cfo and secretary
Mar 04, 2024	risser eric blasius	sold	-813,501	19.7648	-41,159	chief operating officer
Mar 04, 2024	risser eric blasius	acquired	152,250	10.15	15,000	chief operating officer
Mar 04, 2024	spitznagel thomas	sold	-200,000	20.00	-10,000	sr vp, technical ops
Feb 26, 2024	peters jeffrey stuart	sold	-277,655	17.22	-16,124	senior vp and general counsel

Which funds bought or sold MGNX recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 17, 2024	Ikarian Capital, LLC	new	-	4,683,420	4,683,420	0.51%
May 16, 2024	COMERICA BANK	new	-	648	648	-%
May 16, 2024	CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM	added	378	609,534	705,898	-%
May 16, 2024	JANE STREET GROUP, LLC	added	419	4,871,150	5,571,860	-%
May 15, 2024	Integral Health Asset Management, LLC	added	11.11	3,031,000	7,360,000	0.68%
May 15, 2024	Exome Asset Management LLC	sold off	-100	-1,211,160	-	-%
May 15, 2024	Atom Investors LP	reduced	-24.62	205,272	1,543,320	0.19%
May 15, 2024	GOLDMAN SACHS GROUP INC	reduced	-43.96	-846,900	5,097,900	-%
May 15, 2024	DARK FOREST CAPITAL MANAGEMENT LP	new	-	175,050	175,050	0.03%
May 15, 2024	XML Financial, LLC	unchanged	-	54,059	156,029	0.02%

Are Funds Buying or Selling MGNX?

Are funds buying MGNX calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own MGNX

No. of Funds

Unveiling MacroGenics Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	t. rowe price investment management, inc.	9.1%	5,639,994	SC 13G
Feb 14, 2024	armistice capital, llc	7.37%	4,572,000	SC 13G/A
Feb 14, 2024	ra capital management, l.p.	6.5%	4,053,077	SC 13G/A
Feb 13, 2024	bb biotech ag	16.0%	9,929,963	SC 13G/A
Feb 13, 2024	vanguard group inc	6.95%	4,309,394	SC 13G/A
Jan 24, 2024	blackrock inc.	9.9%	6,140,349	SC 13G/A
Oct 30, 2023	ra capital management, l.p.	6.1%	3,764,871	SC 13G
Feb 14, 2023	rtw investments, lp	0%	0	SC 13G/A
Feb 14, 2023	bb biotech ag	14.5%	8,929,963	SC 13G/A
Feb 14, 2023	armistice capital, llc	9.91%	6,092,000	SC 13G

Recent SEC filings of MacroGenics Inc

View All Filings

Date Filed	Form Type	Document
May 09, 2024	10-Q	Quarterly Report
May 09, 2024	8-K	Current Report
May 09, 2024	8-K	Current Report
Apr 08, 2024	4	Insider Trading
Apr 08, 2024	ARS	ARS
Apr 08, 2024	DEF 14A	DEF 14A
Apr 08, 2024	DEFA14A	DEFA14A
Apr 04, 2024	144	Notice of Insider Sale Intent
Apr 03, 2024	8-K	Current Report
Mar 08, 2024	4	Insider Trading

Peers (Alternatives to MacroGenics Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	234.45%	75.34%	-4.58	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

MacroGenics Inc News

Latest updates

MacroGenics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Income Statement (Quarterly)																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	-15.1%	9,104	10,720	10,397	13,136	24,496	73,099	41,734	26,007	11,101	14,147	15,662	30,757	16,881	52,691	18,253	20,257	13,682	25,192	18,741	10,593	9,662
Costs and Expenses	4.6%	62,854	60,074	45,899	58,098	62,922	61,117	66,689	67,815	77,739	72,383	68,649	71,036	68,174	54,861	54,388	67,567	59,127	63,847	56,685	63,562	57,279
S&GA Expenses	-100.0%	-	12,560	12,409	13,692	13,527	13,672	15,355	13,669	16,253	15,583	17,161	15,234	15,036	12,561	9,732	10,216	10,233	11,890	11,833	12,122	10,219
R&D Expenses	-2.8%	46,029	47,351	30,131	43,229	45,872	45,654	48,191	51,744	61,438	55,853	49,823	55,780	53,121	42,300	44,656	57,351	48,894	51,957	44,852	51,440	47,060
Interest Expenses	-	1,133	-	-	774	656	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Income	-13.3%	-52,190	-46,072	17,554	57,469	-38,009	12,802	-24,813	-41,304	-66,443	-58,022	-52,886	-39,935	-51,272	-2,087	-36,043	-46,885	-44,724	-30,396	-44,631	-31,767	-45,017
Net Income Margin	-247.6%	-0.54*	-0.15*	0.41*	0.05*	-0.55*	-0.79*	-2.05*	-3.27*	-3.03*	-2.61*	-1.26*	-1.09*	-	-	-	-	-	-	-	-	-
Free Cashflow	-64.4%	-47,102	-28,657	-35,745	-2,375	-13,192	28,927	-10,226	-50,172	-59,111	-55,684	-16,928	-47,757	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-16.8%	248	298	340	306	343	280	195	218	271	335	392	426	435	379	374	328	265	313	351	384	415
Current Assets	-19.4%	203	251	291	255	289	222	148	168	218	280	335	367	375	313	310	260	195	240	276	288	335
Cash Equivalents	-20.4%	80.00	101	90.00	109	224	109	84.00	21.00	47.00	123	191	189	218	181	202	197	93.00	126	157	180	239
Inventory	2.2%	1.00	1.00	1.00	1.00	1.00	1.00	1.00	3.00	5.00	4.00	4.00	6.00	6.00	-	-	-	-	-	-	-	-
Net PPE	-2.5%	21.00	22.00	23.00	24.00	27.00	30.00	32.00	34.00	36.00	38.00	39.00	39.00	40.00	42.00	41.00	44.00	46.00	48.00	50.00	52.00	55.00
Liabilities	-2.5%	142	146	146	134	234	138	72.00	76.00	93.00	96.00	101	107	85.00	83.00	83.00	80.00	75.00	82.00	96.00	89.00	94.00
Current Liabilities	-0.6%	56.00	56.00	51.00	45.00	46.00	49.00	50.00	51.00	67.00	75.00	69.00	70.00	53.00	51.00	50.00	46.00	40.00	45.00	58.00	50.00	52.00
Shareholder's Equity	-30.4%	106	153	194	172	109	142	123	142	178	240	291	319	351	296	292	248	191	231	255	294	321
Retained Earnings	-4.7%	-1,154	-1,102	-1,056	-1,074	-1,131	-1,093	-1,106	-1,081	-1,040	-973	-915	-863	-823	-771	-769	-733	-686	-642	-611	-567	-535
Additional Paid-In Capital	0.5%	1,261	1,255	1,250	1,245	1,240	1,235	1,229	1,224	1,218	1,213	1,207	1,181	1,173	1,067	1,061	981	877	872	866	861	855
Shares Outstanding	0.8%	63.00	62.00	62.00	62.00	62.00	62.00	61.00	61.00	61.00	60.00	61.00	60.00	-	-	-	-	-	-	-	-	-
Float	-100.0%	-	323	-	-	-	181	-	-	-	1,600	-	-	-	-	-	1,500	-	-	-	830	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-62.8%	-45,643	-28,037	-35,246	-2,089	-12,833	29,320	-9,422	-49,161	-57,696	-54,309	-14,795	-45,690	-29,036	-5,533	-25,677	-36,546	-44,142	-38,044	-17,388	-48,838	-30,000
Share Based Compensation	27.4%	5,553	4,359	4,790	4,391	4,833	4,741	5,123	5,300	5,274	5,412	6,358	6,070	5,286	5,257	5,832	5,096	4,491	5,490	5,398	4,884	3,799
Cashflow From Investing	-36.1%	24,794	38,822	-33,525	-113,476	28,095	-5,788	71,946	23,039	-18,482	-13,553	-2,617	13,818	-34,257	-16,075	-43,281	41,007	10,564	7,626	-6,372	-10,120	-70,492
Cashflow From Financing	-9.2%	248	273	49,911	59.00	100,118	1,359	-	263	37.00	800	18,973	2,346	100,658	1,102	74,063	99,015	162	297	37.00	633	119,005

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

MGNX Income Statement

2024-03-31

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Revenues:
Revenues	$ 9,104	$ 24,496
Costs and expenses:
Cost of product sales	270	113
Cost of manufacturing services	1,846	3,410
Research and development	46,029	45,872
Selling, general and administrative	14,709	13,527
Total costs and expenses	62,854	62,922
Loss from operations	(53,750)	(38,426)
Interest and other income	2,693	1,073
Interest and other expense	(1,133)	(656)
Net loss	(52,190)	(38,009)
Other comprehensive income (loss):
Unrealized gain (loss) on investments	(29)	13
Comprehensive loss	$ (52,219)	$ (37,996)
Net income (loss) per common share:
Basic net loss per common share (in usd per share)	$ (0.84)	$ (0.61)
Diluted net loss per common share (in usd per share)	$ (0.84)	$ (0.61)
Weighted average common shares outstanding:
Basic weighted average common shares outstanding (in shares)	62,290,538	61,809,817
Diluted weighted average common shares outstanding (in shares)	62,290,538	61,809,817
Collaborative and other agreements
Revenues:
Revenues	$ 1,449	$ 16,686
Product sales, net
Revenues:
Revenues	4,861	3,490
Government agreements
Revenues:
Revenues	358	283
Contract Manufacturing
Revenues:
Revenues	2,276	3,615
RevenueFromRoyalityAgreementsMember
Revenues:
Revenues	$ 160	$ 422

MGNX Balance Sheet

2024-03-31

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 80,355	$ 100,956
Marketable securities	103,882	128,849
Accounts receivable	7,219	10,367
Inventory, net	1,248	1,221
Prepaid expenses and other current assets	9,871	9,946
Total current assets	202,575	251,339
Property, equipment and software, net	21,296	21,847
Right-of-use asset	23,229	23,846
Other non current assets	1,185	1,386
Total assets	248,285	298,418
Current liabilities:
Accounts payable	10,694	6,443
Accrued expenses and other current liabilities	18,148	24,239
Deferred revenue	22,837	21,651
Lease liabilities	4,085	3,775
Total current liabilities	55,764	56,108
Deferred revenue, net of current portion	56,182	59,243
Lease liabilities, net of current portion	29,927	30,196
Other non current liabilities	258	258
Total liabilities	142,131	145,805
Stockholders' equity:
Common stock, $0.01 par value -- 125,000,000 shares authorized, 62,560,502 and 62,070,627 shares outstanding at March 31, 2024 and December 31, 2023, respectively	626	621
Additional paid-in capital	1,260,505	1,254,750
Accumulated other comprehensive loss	(35)	(6)
Accumulated deficit	(1,154,942)	(1,102,752)
Total stockholders' equity	106,154	152,613
Total liabilities and stockholders' equity	$ 248,285	$ 298,418

About MacroGenics Inc

MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 Ãƒâ€” CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. In addition, it develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3;Retifanlimab, an monoclonal antibody used for cancer therapeutics; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B Ãƒâ€” CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.

CEO	Dr. Scott Koenig M.D., Ph.D.
WEBSITE	macrogenics.com
INDUSTRY	Biotechnology
EMPLOYEES	357

MacroGenics Inc Frequently Asked Questions

What is the ticker symbol for MacroGenics Inc? What does MGNX stand for in stocks?

MGNX is the stock ticker symbol of MacroGenics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of MacroGenics Inc (MGNX)?

As of Fri May 17 2024, market cap of MacroGenics Inc is 273.08 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of MGNX stock?

You can check MGNX's fair value in chart for subscribers.

What is the fair value of MGNX stock?

You can check MGNX's fair value in chart for subscribers. The fair value of MacroGenics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of MacroGenics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for MGNX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is MacroGenics Inc a good stock to buy?

The fair value guage provides a quick view whether MGNX is over valued or under valued. Whether MacroGenics Inc is cheap or expensive depends on the assumptions which impact MacroGenics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for MGNX.

What is MacroGenics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, MGNX's PE ratio (Price to Earnings) is -11.75 and Price to Sales (PS) ratio is 6.3. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. MGNX PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on MacroGenics Inc's stock?

In the past 10 years, MacroGenics Inc has provided -0.135 (multiply by 100 for percentage) rate of return.